RankAlpha logo
Back to Rankings

ABBV

AbbVieC
NYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
View Chart
Current thesis
Stronger-than-expected uptake for new immunology and oncology launches, sustained margins, and continued dividends and buybacks that lift multiples and total return.
Posture
Mixed
Lead driver
Value
What changed
Next scheduled catalyst: earnings 2026-10-30 · BMO.
What can break
High debt levels / refinancing risk in adverse market
Momentum
92
Value
60
Sentiment
33
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $227.23 · Bull $264.73 · Bear $185.31Analysis 2025-09-27; returns require an exact persisted reference.
Earnings
33 · Non-qualifying
Next 2026-10-30 · BMO
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-26 • Vendor: Data Vendor v1
Scores
As of 2026-10-23 • Model: HYBRID_IC_RP
AI Memo
As of 2025-09-27 • Model: RankAlpha Sentiment AI
Earnings Setup
As of 2026-10-27 • RankAlpha AI
Investment thesis
As of 2026-10-23

Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-23. Definitions

Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $285.00
Why
Momentum92 · Δ7d -4.6
Value60 · Δ7d -0.0
Sentiment33 · Δ7d +0.5
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Earnings surprise screen
33Non-qualifying2026-10-30 bmo
View setup

AbbVie has a confirmed before-open date and reported EPS and revenue consensus, while its company filing provides updated 2026 EPS guidance. Checked sources do not confirm a positive current-quarter revision/whisper signal or revenue upside; the recent price path is modestly negative and the available tape does not verify >1.5x accumulation volume.

Screen as of 2026-10-27. Window 2026-10-27 to 2026-11-02.

Confirming evidence

  • • Next scheduled catalyst: earnings 2026-10-30 · BMO.
  • • Pre-earnings setup: 33 / non-qualifying.
  • • Value remains the lead driver in the composite, 7D delta -0.0.

Contradictions & invalidation

  • • High debt levels / refinancing risk in adverse market
  • • Humira biosimilar market share and pricing pressure
  • • Faster-than-expected Humira biosimilar erosion, negative late-stage readouts or regulatory delays, and margin contraction that compresses valuation multiples.

Catalyst clock

2026-10-30 · BMO

Quarterly earnings / guidance update

Lead driver: Value · See fundamentals
Momentum
92
8% active weight
Current posture
7d trendSoftening
Δ7d
-4.6
Δ21d
+9.1
Value
60
47% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
-1.1
Sentiment
33
45% active weight
Current posture
7d trendFlat
Δ7d
+0.5
Δ21d
-12.8
Why this grade

Composite grade C. Momentum 91.8 / Value 59.7 / Sentiment 33.1

Scenario snapshot

Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2025-09-27. Scenario method

B+
Bull case
20%
Probability
Target price
$264.73
Analysis reference price unavailable
Analysis 2025-09-27 · RankAlpha Sentiment AI
Most likely
B
Base case
60%
Probability
Target price
$227.23
Analysis reference price unavailable
Analysis 2025-09-27 · RankAlpha Sentiment AI
B-
Bear case
20%
Probability
Target price
$185.31
Analysis reference price unavailable
Analysis 2025-09-27 · RankAlpha Sentiment AI
Fundamentals (TTM)
As of 2026-10-26
Market Cap
$506.7B
Beta
0.34
Shares Out
1.77B
P/E (TTM)
166.1
P/S (TTM)
6.52
P/FCF (TTM)
47.54
Rev YoY
+10.2%
EPS YoY
+288.0%
Gross Margin
+71.4%
Op Margin
+34.2%
Net Debt
$63.12B
Current Ratio
0.81
As of 2026-10-23 • Updated nightlySource: Internal modelMethods & Data